Harrow's IHEEZO® Shows Significant Reduction in Patient Discomfort Post-Intravitreal Injections
Event summary
- Harrow's IHEEZO® demonstrated a 58% reduction in patient-reported discomfort compared to proparacaine ophthalmic solution in a randomized contralateral-eye study.
- The study involved 100 eyes from 50 patients undergoing same-day bilateral intravitreal injections.
- Discomfort scores were significantly lower at all four post-injection assessments (p≤0.048).
- The largest absolute differences in discomfort were observed immediately after injection (1.44 vs. 3.06 at two minutes).
- The study was conducted by Retina Consultants of Delmarva, with Travis Peck, MD, as the principal investigator.
The big picture
Harrow's study results highlight the growing importance of patient comfort in ophthalmic procedures, particularly for intravitreal injections which are frequently repeated. This aligns with broader industry trends towards patient-centric care and differentiated product offerings in the ophthalmology sector. The study's findings could strengthen Harrow's position in the market, especially among retina specialists managing high volumes of patients requiring ongoing treatment.
What we're watching
- Market Adoption
- Whether retina specialists will broadly adopt IHEEZO® given its demonstrated improvement in patient comfort.
- Competitive Positioning
- How Harrow will leverage these results to differentiate IHEEZO® from legacy ophthalmic anesthesia modalities.
- Regulatory Compliance
- The pace at which Harrow can address ongoing communications with the FDA regarding compliance and quality plans at its outsourcing facility.